| Date | Form | Description | Docs | XBRL | Pages |
| 09/16/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/16/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/12/19 | DEF 14A | Definitive proxy statements |
|
46 | |
| 09/06/19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
84 |
| 08/27/19 | 8-K | Current report filing |
|
13 | |
| 08/21/19 | 8-K | Current report filing |
|
25 | |
| 07/18/19 | 8-K | Current report filing |
|
4 | |
| 06/21/19 | EFFECT | Notice of Effectiveness |
|
1 | |
| 06/19/19 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 06/18/19 | UPLOAD | SEC-generated letter |
|
1 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...